Emrosi Capsule
NDC Package 69489-131-07

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Emrosi (minocycline hydrochloride extended-release) capsules is eMROSI is indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults.Limitations of UseThis formulation of minocycline has not been evaluated in the treatment or prevention of infections. This formulation utilizes a capsule delivery system. Marketed by Journey Medical Corporation, this product is identified by NDC 69489-131 and is authorized under FDA application NDA219015.

Identification & Billing

NDC Package Code
69489-131-07
Package Description
7 CAPSULE in 1 BOTTLE
Product Code
69489-131
11-Digit Billing Format
69489013107
RxNorm Crosswalk
  • RxCUI: 2706371 - minocycline 40 MG 24 HR Extended Release Oral Capsule
  • RxCUI: 2706371 - 24 HR minocycline 40 MG Extended Release Oral Capsule
  • RxCUI: 2706371 - 24 HR minocycline 40 MG (as minocycline hydrochloride) Extended Release Oral Capsule
  • RxCUI: 2706378 - emrosi 40 MG 24HR Extended Release Oral Capsule
  • RxCUI: 2706378 - 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi]

Clinical Specifications

Proprietary Name
Emrosi
Non-Proprietary Name
Minocycline Hydrochloride Extended-release
Substance Name
Minocycline Hydrochloride
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
MINOCYCLINE HYDROCHLORIDE 40 mg/1
Pharmacologic Class
Usage Information
EMROSI is indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults.Limitations of UseThis formulation of minocycline has not been evaluated in the treatment or prevention of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, use EMROSI only as indicated.

Regulatory & Marketing

Labeler Name
Journey Medical Corporation
Product Type
Human Prescription Drug
FDA Application #
NDA219015
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
03-01-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (69489-131). Click a package code to view its specific billing and regulatory data.

69489-131-30
30 CAPSULE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 69489-131-07 identifies a specific commercial package of 7 capsule in 1 bottle of Emrosi, a human prescription drug labeled by Journey Medical Corporation. This capsule is formulated for oral use and contains minocycline hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Journey Medical Corporation on March 01, 2025. The current certification is valid through December 31, 2026.

How is this Journey Medical Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 69489013107. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
69489-131-07
11-Digit CMS (5-4-2)
69489-0131-07

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.